Drug Profile
Albutrepenonacog alfa - CSL Behring
Alternative Names: Albumin fusion protein - CSL Behring; CSL 640; CSL-654; Factor IX (Recombinant) - CSL; Idelvion; Recombinant coagulation factor IX - CSL Behring; Recombinant factor IX - CSL Behring; Recombinant factor IX fusion protein linked with human albumin; rFIX-FP - CSL Behring; rIX-FPLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator CSL Behring
- Class Albumins; Antihaemorrhagics; Blood coagulation factors; Recombinant fusion proteins
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemophilia B
Most Recent Events
- 02 Jun 2021 CSL Behring completes a phase III trial for Haemophilia B in Australia, Austria, Bulgaria, Canada, Czech Republic, Italy, France, Germany, Japan, Israel, Malaysia, Philippines, South Africa, Spain and USA (IV) (NCT02053792)
- 03 Jul 2020 The European Medicines Agency approves a 21-day dosing regimen for albutrepenonacog alfa for Haemophilia B
- 28 Mar 2020 No recent reports of development identified for clinical-Phase-Unknown development in Haemophilia in Unknown (SC)